{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"groups":[{"description":"Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels\n\nepoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.","id":"OG000","title":"Epoetin Alfa - 80,000 U sc"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline to Day 28","title":"Number of Patients With an at Least 2gm/dL Increase in Hgb","type":"PRIMARY","unitOfMeasure":"participants"}